Petros Pharmaceuticals, Inc.

PTPI Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue grew 1,070.6%, EPS grew 76.7% and free cash flow grew 71.3%, each against the same quarter a year earlier.

0.00 0.00 NaN
Market cap
$1.0M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
4/9
Altman Z
−16.96
Beneish M
−3.26
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(710.28%) 1,085.80% 1,900.89% (1,475.74%)

+8 more TTM periods

ROA
(334.15%) (385.60%) (553.07%) (356.67%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(2,608.36%) (2,394.50%) (1,521.79%) (1,420.44%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.08) (0.13) (0.24) (0.11)
Free Cash Flow
(3.72) (5.86) (6.73) (4.84)
Other line items

Show all line items

Columns are period end dates